<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573049</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1357</org_study_id>
    <nct_id>NCT04573049</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China International Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the effectiveness and safety of levosimendan compared with placebo in&#xD;
      subjects with severe aortic stenosis and heart failure undergoing transcatheter aortic valve&#xD;
      replacement&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The number of subjects undergoing transcatheter aortic valve replacement to treat aortic&#xD;
      stenosis have been increasing in recent decades. Levosimendan, an innovative inotrope, is&#xD;
      powerfully evidenced to have the function to improve cardiac output and hemodynamic&#xD;
      parameters. However, there is no specified study concentrated on the role of Levosimendan in&#xD;
      surgical procedure such as transcathter aortic intervention. This double-blind, randomized,&#xD;
      placebo-controlled study is aimed to investigate the effectiveness and safety of Levosimendan&#xD;
      in adults having severe aortic stenosis combined with heart failure undergoing transcatheter&#xD;
      aortic valve replacement. Therefore, the purpose of this trial is to explore whether the&#xD;
      improvement of cardiac and renal performance can be rendered by intra-operative Levosimendan&#xD;
      infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of NT-proBNP level</measure>
    <time_frame>day 1, day 3, day 5, month 1 and month 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of CK-MB</measure>
    <time_frame>day 1, day 3, day 5, month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of c-TnI</measure>
    <time_frame>day 1, day 3, day 5, month 1 and month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of left ventricular ejection fraction</measure>
    <time_frame>day 1, day 3, day 5, month 1 and month 3</time_frame>
    <description>It is evaluated by echcardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of left ventricular end-diastolic diameter</measure>
    <time_frame>day 1, day 3, day 5, month 1 and month 3</time_frame>
    <description>It is evaluated by echcardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of patients in need of secondary intra-operative vasoactive-inotropic substances</measure>
    <time_frame>Peri-operation</time_frame>
    <description>Vasoactive-inotropic substances include dobutamine, milrinone, epinephrine, dopamine and vasopressors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of postoperative kidney injury</measure>
    <time_frame>day 1, day 3, day 5, month 1 and month 3</time_frame>
    <description>The kidney injury will be assessed by the change of serum creatinine, urea nitrogen and cystatin C.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>Peri-operation</time_frame>
    <description>Adverse events include hypotension and arrythmia.</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of atrial fibrillation</measure>
    <time_frame>Peri-operation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change of electrolyte</measure>
    <time_frame>Peri-operation</time_frame>
    <description>The change of electrolyte is evaluated by potassium, calcium and lactic acid level.</description>
  </other_outcome>
  <other_outcome>
    <measure>The number of patients having liver dysfunction</measure>
    <time_frame>Peri-operation</time_frame>
    <description>Liver dysfunction is assessed by the change of alanine aminotransferase (ALT) and aspartate aminotransferase (AST).</description>
  </other_outcome>
  <other_outcome>
    <measure>The length of intensive care unit stay</measure>
    <time_frame>From date of surgery until intensive care unit discharge (assessed up to 1 month)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>In-hospital medical expense</measure>
    <time_frame>From baseline until hospital discharge (assessed up to 1 month)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Failure</condition>
  <condition>Inotropic Agents</condition>
  <condition>Safety Issues</condition>
  <condition>Effect of Drug</condition>
  <condition>Cardiac Event</condition>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levosimendan 0.1µg/kg/min will last for 24h after the valve is released.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5% glucose 0.1µg/kg/min administration will continue for 24h after the valve is released.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed (by the subjects or their legally acceptable representatives) informed consent&#xD;
             document indicating that they understand the purpose of and procedures required for&#xD;
             the study and are willing to participate in the study&#xD;
&#xD;
          2. Severe aortic stenosis&#xD;
&#xD;
               1. Mean transaortic gradient ≥ 40 mmHg(at rest or stress)&#xD;
&#xD;
               2. Aortic peak velocity ≥ 4m/s;&#xD;
&#xD;
               3. Arotic valve area &lt;0.8 cm2 and/or aortic valve area index&lt; 0.5cm2/m2&#xD;
&#xD;
          3. Cardiac dysfunction&#xD;
&#xD;
               1. LVEF≤50% (estimated by Simpson)&#xD;
&#xD;
               2. NT-proBNP≥1500ng/L；&#xD;
&#xD;
               3. Symptoms of dyspnea and fatigue when at rest or after slight exertion (New York&#xD;
                  Heart Association ≥ Ⅲ -Ⅳ)&#xD;
&#xD;
               4. Intermittant fluid retention and/or symptoms induced by low cardiac output at&#xD;
                  rest, but lack of hemodynamic instability&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated acute cardiac failure due to hemodynamic instability&#xD;
&#xD;
          2. A historty of torsade de points ventricular tachycardia&#xD;
&#xD;
          3. Known allergic reaction or sensitivity to Levosimendan or excipients&#xD;
&#xD;
          4. Received levosimendan within 1 week prior to the planned clinical trial&#xD;
&#xD;
          5. Serum potassium &lt; 3.5 mmol/L and &gt; 5.5 mmol/L before the drug study&#xD;
&#xD;
          6. Systolic blood pressure &lt; 90mmHg at baseline&#xD;
&#xD;
          7. Estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m2.&#xD;
&#xD;
          8. Unable to participate in study for being critically ill asssed by clinicians&#xD;
&#xD;
          9. Other concomitant severe morbidities leading to poor prognosis and decreased&#xD;
             mortality, such as malignant tumor and disease involving other vital organs; life&#xD;
             expectancy less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianhui Wang, MD</last_name>
    <phone>010-88398082</phone>
    <email>stewenwang@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jianhui Wang</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhui Wang, MD</last_name>
      <phone>010-88398082</phone>
      <email>stewenwang@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 27, 2020</last_update_submitted>
  <last_update_submitted_qc>September 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China National Center for Cardiovascular Diseases</investigator_affiliation>
    <investigator_full_name>Jianhui Wang</investigator_full_name>
    <investigator_title>Principle Investigator and Clinical professor</investigator_title>
  </responsible_party>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Levosimendan</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <keyword>NT-proBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

